Abstract
Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular-targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimelry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for 90Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for 90Y to 1% for 177Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 436-449 |
| Number of pages | 14 |
| Journal | Cancer Biotherapy and Radiopharmaceuticals |
| Volume | 20 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2005 |
Fingerprint
Keywords
- Pm
- Ho
- Lu
- Re
- Cu
- Y
- Beta-emitter dosimetry
- MCNP
- Medical Internal Radiation Dose (MIRD) estimates
- Molecular targeted radionuclide therapy
- Mouse model
- Radioimmunotherapy
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
- Oncology
Cite this
Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. / Miller, William H.; Hartmann-Siantar, Christine; Fisher, Darrell; Descalle, Marie Anne; Daly, Tom; Lehmann, Joerg; Lewis, Michael R.; Hoffman, Timothy; Smith, Jeff; Situ, Peter D.; Volkert, Wynn A.
In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 20, No. 4, 2005, p. 436-449.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides
AU - Miller, William H.
AU - Hartmann-Siantar, Christine
AU - Fisher, Darrell
AU - Descalle, Marie Anne
AU - Daly, Tom
AU - Lehmann, Joerg
AU - Lewis, Michael R.
AU - Hoffman, Timothy
AU - Smith, Jeff
AU - Situ, Peter D.
AU - Volkert, Wynn A.
PY - 2005
Y1 - 2005
N2 - Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular-targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimelry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for 90Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for 90Y to 1% for 177Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.
AB - Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular-targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimelry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for 90Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for 90Y to 1% for 177Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.
KW - Pm
KW - Ho
KW - Lu
KW - Re
KW - Cu
KW - Y
KW - Beta-emitter dosimetry
KW - MCNP
KW - Medical Internal Radiation Dose (MIRD) estimates
KW - Molecular targeted radionuclide therapy
KW - Mouse model
KW - Radioimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=24044535093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24044535093&partnerID=8YFLogxK
U2 - 10.1089/cbr.2005.20.436
DO - 10.1089/cbr.2005.20.436
M3 - Article
C2 - 16114992
AN - SCOPUS:24044535093
VL - 20
SP - 436
EP - 449
JO - Cancer Biotherapy and Radiopharmaceuticals
JF - Cancer Biotherapy and Radiopharmaceuticals
SN - 1084-9785
IS - 4
ER -